MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/jtd-2026-0895

Медицинская библиотека · Journal of thoracic disease · 2026

Perioperative FLOT chemotherapy for locally advanced esophageal adenocarcinoma: from ESOPEC to daily practice-a retrospective cohort study.

Bouckaert Andreas, Van Herpe Filip, Moons Johnny, Vanstraelen Stijn, Dekervel Jeroen, Depypere Lieven, Lerut Toni, Mandeville Yannick, Seurs Ward, Van Veer Hans, Nafteux Philippe

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Two neoadjuvant treatment strategies exist for esophageal and gastro-esophageal junction (GEJ) adenocarcinoma: Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) chemoradiotherapy or peri-operative FLOT chemotherapy (5-fluorouracil, leucovorin, oxaliplatin, docetaxel). ESOPEC showed improved overall survival (OS) after FLOT. This study aimed to reassess OS after perioperative FLOT and surgery in real-life.

METHODS

This single center retrospective cohort study included all patients with locally advanced esophageal or GEJ adenocarcinoma (cT1/2N+ or cT3/4N0/+) treated with intended perioperative FLOT and surgery between 2017 and 2023. Primary endpoint was OS.

RESULTS

One-hundred forty-four patients were included with mostly high T-stages [cT3 (n=120, 83.3%), cT4 (n=14, 9.7%)] and node-positive tumors [cN1 (n=37, 25.7%), cN2 (n=60, 41.7%), cN3 (n=19, 13.2%)]. Nineteen patients (13.2%) didn't proceed to surgery (PRE), and 19 patients (15.2%) did not receive any postoperative FLOT (PRE-SURG). Finally, 96 (76.8%) started postoperative FLOT (PRE-SURG-POST). Median OS was 53.3 months and after stratification 12.9 months [95% confidence interval (CI): 11.1-14.7] for PRE and 13.0 months (95% CI: 5.6-20.5) for PRE-SURG. Median OS for PRE-SURG-POST was not reached but significantly higher (P<0.001). Median event-free survival (EFS) was 29.6 months for PRE-SURG-POST, compared with 12.4 months (95% CI: 8.8-15.9) for PRE-SURG (P=0.06) and 7.7 months (95% CI: 1.0-14.4) for PRE (P<0.0001).

CONCLUSIONS

Our results, with predominantly advanced and node positive tumors, corroborate the OS and EFS of perioperative FLOT with surgery observed in the FLOT-4 and ESOPEC-trial. Completion of treatment was associated with improved OS and EFS. This emphasizes the importance of patient selection, high-quality surgery and supportive care to maximize treatment continuation and increasing survival.

Для цитирования: Bouckaert Andreas, Van Herpe Filip, Moons Johnny, Vanstraelen Stijn, Dekervel Jeroen, Depypere Lieven, Lerut Toni, Mandeville Yannick, Seurs Ward, Van Veer Hans, Nafteux Philippe. Perioperative FLOT chemotherapy for locally advanced esophageal adenocarcinoma: from ESOPEC to daily practice-a retrospective cohort study.. Journal of thoracic disease. 2026. DOI: 10.21037/jtd-2026-0895.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.